IFNG and sarcoidosis: Conversely, clinical improvements in granuloma annulare as well as sarcoidosis have most profoundly been achieved by inhibition of IFN-γ-downstream signaling via JAK/STAT pathways using specific inhibitors, such as tofacitinib [15,27,35,56].